I am a member of the Leukemia Research Program at the OSUCCC – James, where my research broadly covers translational and clinical pharmacology of anticancer agents. I also hold the Gertrude Parker Heer Chair in Cancer Research.
Recently, my laboratory has focused on the preclinical development of anticancer agents for the treatment of acute myeloid leukemia (AML), with an emphasis on tyrosine kinase inhibitor (TKI) drug combinations.
I am also interested in studying developmental therapeutics for AML, clinical pharmacology of tyrosine kinase inhibitors, variability in anticancer drug disposition and investigational anticancer drug development.
I have authored or co-authored publications in several scientific journals, including Cancer Research, Leukemia, Clinical Pharmacology & Therapeutics, Journal of Clinical Investigation and Nature Communications.

Professional Interests
Dr. Baker’s cancer-relevant research interests broadly cover translational and clinical pharmacology of anti-cancer agents. Recently, her laboratory has focused on the preclinical development of anti-cancer agents for the treatment of acute myeloid leukemia (AML), with an emphasis on tyrosine kinase inhibitor (TKI) drug combinations. Dr. Baker’s research interests include developmental therapeutics for AML, clinical pharmacology of tyrosine kinase inhibitors, variability in anti-cancer drug disposition and investigational anti-cancer drug development.

Honors
Clinical and Translational Science Award, 2017